|
MRI News Service:
Contrast Agents p17 |
|
|
|
 |
 | | | 'Formation of new blood vessels, also known as angiogenesis, is crucial for sustained tumor growth and cancer metastasis. Recently, clinically available therapies to suppress the growth of these vessels have been available to improve patient survival in ...' | | Monday, 26 July 2010 by www.sciencedaily.com |
|
|
|
| | | ' Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that it has acquired the balance of the worldwide rights for gadofosveset trisodium, a unique, injectable magnetic resonance angiography (MRA) blood pool ...' | | | Monday, 12 July 2010 by www.radiopharm.com | |
|
|
|
| | | 'Clusters of heated, magnetic nanoparticles targeted to cell membranes can remotely control ion channels, neurons and even animal behavior, according to a paper published by University at Buffalo physicists in Nature Nanotechnology.The research could ...' | | | Tuesday, 6 July 2010 by http://www.sciencedaily.com/releases/2010/07/100706150626.htm | |
|
|
|
| | | 'Though an estimated 8 million to 12 million people in the United States have been diagnosed with peripheral vascular disease (PVD), the number of people affected by this disease that causes narrowing of the blood vessels outside the heart and brain is ...' | | | Thursday, 1 July 2010 by www.radiologytoday.net | |
|
|
|
| | | 'AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Takeda Pharmaceutical Company Limited (TSE: 4502) today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use. On June 1, 2010, AMAG submitted a ...' | | | Tuesday, 29 June 2010 by www.snl.com | |
|
|
|
| | | 'Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the first national contract signed for ABLAVAR® with Amerinet, Inc., a leading national healthcare group purchasing organization. ABLAVAR® (gadofosveset ...' | | | Thursday, 3 June 2010 by www.businesswire.com | |
|
|
|
| | | 'The Centre for Cooperative Research in Biomaterials, CIC biomaGUNE, is involved in the research consortium of cvREMOD, which aims to move forward in the attainment of new diagnosis techniques for prevention and customised treatment of cardiovascular ...' | | | Thursday, 20 May 2010 by www.eurekalert.org | |
|
|
|
| | | 'Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal ...' | | | Monday, 19 April 2010 by www.eurekalert.org | |
|
|
|
| | | 'For several years a company initially called Advanced Magnetics (and later known as AMAG Pharma), with its partners, spent a good deal of money developing and seeking approval of a product called ferumoxtran-10. Ferumoxtran-10 was an imaging agent ...' | | | Wednesday, 24 March 2010 by www.wellsphere.com | |
|
|
|
| | | 'In response to concern over gadolinium-based contrast agents, Little Company of Mary, a not-for-profit Catholic community hospital in Evergreen Park, Ill., wanted to provide the highest quality and safest MRA procedures to its patients. To accomplish ...' | | | Thursday, 25 February 2010 by medical.toshiba.com | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
When choosing between two evils, I always like to try the one I've never
tried before.
- Mae West |
|
|
News
top
